Latest Glutamate carboxypeptidase II Stories
Adding the dietary supplements folate and vitamin B12 to treatment with antipsychotic medication improved a core symptom component of schizophrenia in a study of more than 100 patients.
Johns Hopkins researchers report the successful use of a form of MRI to identify what appears to be a key biochemical marker for cognitive impairment in the brains of people with multiple sclerosis (MS).
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel -- undetected by normal cells -- through the bloodstream until activated by specific cancer proteins.
Progress toward understanding the role of sex hormones in the growth of prostate cancerâ€”the most common cancer in U.S. menâ€”has been hindered by the lack of a suitable laboratory research model.
Study could lead to more effective treatment and therapy for prostate cancer as a result of a new molecular imaging technique that targets prostate tumor cells.
Glutamate is to the brain like coffee is to our bodies. A cup of Joe in the morning can wake us, but overloading on caffeine causes the stimulant to work against us.
A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease.
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the initiation of a phase 1 dose-escalation clinical study of its prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC). PSMA ADC is an investigational therapy that combines a prostate-cancer antibody with a cancer drug.
US-based biopharmaceutical company Progenics Pharmaceuticals has initiated a Phase I dose-escalation clinical study of its prostate-specific membrane antigen antibody-drug conjugate.